Management of chronic hepatitis C treatment failures: role of consensus interferon.
A significant proportion of patients with chronic hepatitis C virus (HCV) infection who undergo antiviral therapy have persistent or recurrent viremia and fail to achieve a sustained virologic response (SVR). Factors associated with treatment failure include HCV genotype 1 infection, high serum HCV RNA levels, and advanced fibrosis. Consensus interferon (CIFN) is a synthetic type I interferon derived from a consensus sequence of the most common amino acids found in naturally occurring alpha interferon subtypes. Several prospective clinical studies have demonstrated that CIFN may be a treatment option in patients who have failed prior interferon-based therapy, including those who have failed combination therapy with standard interferon or peginterferon plus ribavirin. Daily CIFN in combination with ribavirin may be an effective regimen in this setting; however, optimal dose and treatment duration of CIFN therapy have not been well established. Patients who achieve viral suppression during prior interferon-based therapy and those who do not have advanced fibrosis have a greater likelihood of achieving a SVR with CIFN retreatment. Individualized therapy targeting specific patient groups will be an important consideration in the successful management of prior treatment failures. Additional prospective studies are required in order to identify optimal treatment strategies for the use of CIFN in these patients.
Gonzalez
Stevan A
SA
Division of Hepatology, Baylor Regional Transplant Institute, Baylor All Saints Medical Center, Fort Worth and Baylor University Medical Center, Dallas, TX, USA.
Keeffe
Emmet B
EB
N Engl J Med. 1986 Dec 18;315(25):1575-8
3097544
Hepatology. 2004 Apr;39(4):1147-71
15057920
Hepatol Res. 2003 Dec;27(4):253-259
14662112
J Hepatol. 2005 Aug;43(2):243-9
16082735
J Interferon Cytokine Res. 1996 Jul;16(7):489-99
8836913
Am J Gastroenterol. 1999 Dec;94(12):3583-8
10606323
Ann Intern Med. 2004 Mar 2;140(5):346-55
14996676
Lancet. 1998 Oct 31;352(9138):1426-32
9807989
J Hepatol. 2006 Feb;44(2):291-301
16360972
Clin Liver Dis. 2005 May;9(2):329-46, viii
15831277
Hepatology. 2003 Sep;38(3):645-52
12939591
Liver Int. 2006 Apr;26(3):319-25
16584394
Gut. 2006 Nov;55(11):1631-8
16709661
Dig Liver Dis. 2007 Jan;39(1):47-51
17079197
J Virol. 2004 Aug;78(15):8219-28
15254193
J Hepatol. 2007 Apr;46(4):596-604
17218037
Gastroenterology. 2008 Sep;135(3):821-9
18593587
Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947
15057741
N Engl J Med. 2004 May 27;350(22):2265-71
15163776
N Engl J Med. 1998 Nov 19;339(21):1485-92
9819446
Dig Dis Sci. 2007 Jun;52(6):1540-7
17406822
Lancet. 2001 Sep 22;358(9286):958-65
11583749
J Viral Hepat. 2002 Sep;9(5):334-9
12225327
Hepatology. 1997 Sep;26(3):747-54
9303508
Dig Dis Sci. 2006 Nov;51(11):1956-61
17004124
Gastroenterology. 2006 Apr;130(4):1086-97
16618403
Gastroenterology. 2006 Apr;130(4):1098-106
16618404
J Hepatol. 2003 Nov;39(5):843-9
14568269
World J Gastroenterol. 2006 Nov 14;12(42):6861-4
17106937
Gastroenterology. 2002 May;122(5):1303-13
11984517
Nature. 2005 Aug 18;436(7053):939-45
16107833
Hepatology. 1998 Apr;27(4):1136-43
9537455
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Am J Gastroenterol. 2008 Nov;103(11):2727-36; quiz 2737
18684170
J Gastroenterol. 2002;37(9):732-6
12375147
Eur J Gastroenterol Hepatol. 2002 May;14(5):477-83
11984144
Dig Dis Sci. 2005 Apr;50(4):727-32
15844709
Dig Dis Sci. 2008 Jul;53(7):1961-6
18219576
Am J Gastroenterol. 2005 Nov;100(11):2453-62
16279900
Can J Gastroenterol. 2003 Aug;17(8):479-82
12945008
Hepatology. 2002 Nov;36(5 Suppl 1):S35-46
12407575
Hepatology. 1999 Aug;30(2):562-6
10421669